Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
Rhea-AI Summary
Vericel (NASDAQ:VCEL) received a ten-year BARDA contract valued at up to $197 million, effective April 1, 2026. The agreement includes a $35 million base period and about $10 million for initial procurement and Vendor Managed Inventory (VMI) over 12 months.
The contract covers procurement of NexoBrid, VMI establishment, design/validation of a potential U.S. manufacturing facility, and development of a room-temperature stable formulation and an expanded blast trauma indication.
Positive
- Contract value up to $197 million over ten years
- Base period funding of $35 million, including $10 million next 12 months
- Procurement to expand U.S. Strategic National Stockpile
Negative
- Optional awards not guaranteed; future funding contingent on BARDA decisions
- U.S. manufacturing facility design and validation are planned, not completed
News Market Reaction – VCEL
In the Apr 2 session, VCEL gained 4.85%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Facility FDA approval | Positive | +1.7% | FDA approved new MACI manufacturing facility, expanding long-term capacity. |
| Mar 03 | Investor conferences | Neutral | -2.7% | Company scheduled presentations at major March healthcare investor conferences. |
| Feb 26 | Q4/FY25 earnings | Positive | +1.6% | Reported strong 2025 revenue, margins, EBITDA and provided 2026 guidance. |
| Feb 12 | Earnings date set | Neutral | -1.9% | Announced timing and access details for upcoming Q4/FY25 earnings call. |
| Jan 13 | Prelim 2025 results | Positive | +1.3% | Preliminary 2025 results highlighted strong MACI growth and profitability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational and financial updates have recently coincided with modest positive price reactions, while neutral calendar/conference items saw small pullbacks.
Over the past few months, Vericel reported strong 2025 financials with total revenue of $276.3M, MACI revenue of $239.5M, and adjusted EBITDA of $70.9M, alongside solid cash of about $200M and no debt. Earnings and preliminary results on Jan 13 and Feb 26 both saw positive next-day moves. FDA approval of a new MACI manufacturing facility on Mar 4 also drew a modest gain. In contrast, conference and earnings-date announcements prompted small declines.
Key Terms
vendor managed inventory technical
strategic national stockpile regulatory
blast trauma injuries medical
mass casualty events medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to
The base period contract of
“We are very pleased to partner with BARDA to support U.S. national preparedness for potential mass casualty events involving severe thermal burns and blast trauma injuries,” said Nick Colangelo, President and CEO of Vericel. “We believe that this contract demonstrates the significant clinical value of NexoBrid and will support the continued expansion of NexoBrid utilization in the U.S.”
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.
About BARDA
The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies and diagnostic tools for public health medical emergencies. For more information, refer to www.phe.gov/about/BARDA. The procurement and further development of NexoBrid pursuant to this program has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Center for the Biomedical Advanced Research and Development Authority, under contract no. 75A50126C00002.
Forward-Looking Statements
Vericel cautions you that all statements other than statements of historical fact included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with the potential benefits of the agreement with BARDA and the availability of funding from BARDA, timing and conduct of clinical trial and product development activities, competitive developments, changes in third-party coverage and reimbursement, including recent and future healthcare reform measures and private payor initiatives, physician and burn center adoption of NexoBrid, labor strikes, supply chain disruptions or other world events or factors that might affect the supply of sufficient quantities of NexoBrid to meet customer demand, changes in trade policies and regulations, including the potential for increases or changes in duties, current and potentially new tariffs or quotas, lingering effects of adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, possible changes in governmental monetary and fiscal policies, including, but not limited to, Federal Reserve policies in connection with continued inflationary pressures, the impact from future regulatory, judicial and legislative changes to our industry or to the broader business landscape, including those included in the One Big Beautiful Bill Act, global geopolitical tensions and potential future impacts on our business or the economy generally stemming from a public health emergency.
These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on February 26, 2026, and in other filings with the SEC. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
